Designing with the Patient in Mind: Amplifying the Patient Voice in Medicines Development and Approval

Winselow Tucker is the Senior Vice President, Intercontinental, at Bristol Myers Squibb (BMS). He is passionate about delivering innovative pharmaceutical products to patients suffering from serious and rare diseases such as cancer. Winselow has 20 years of pharmaceutical and biotech experience delivering strong business results and successfully launching new products. Given his passion he has spent most of his career in the commercialization of oncology products.

In his current role, Winselow oversees a diverse and dynamic multi-national region, with responsibilities for 70+ countries across five continents, including China, Asia, Australia, Central & Eastern Europe, Latin America, Brazil and the Middle East. 

Before becoming the Head of Intercontinental in January 2022, overseeing 70+ markets across five continents, Winselow was the General Manager of BMS’ US Hematology business. In this role, he led the U.S. commercial operations for the Hematology franchise and was responsible for driving the performance of key marketed brands and delivering the next wave of innovative medicines to patients.

Before joining BMS, Winselow was General Manager, Canada, for Novartis Oncology where he led the organization to deliver strong results despite the loss of exclusivity on key strategic brands. Prior to this role, Winselow held senior positions in Global Marketing at Novartis Oncology including Vice President of the Breast Cancer franchise and Interim Head Global Marketing.

Winselow has also held senior commercial leadership positions across both large pharmaceutical and biotech companies.

Neil has over 25 years’ experience in bringing the patient voice to life for healthcare decision makers. Neil has been a patient advocate, and is the past chair of HTAi’s patient & citizen involvement group where he continues to work with HTA bodies around the world on improvements to patient engagement in HTA. Neil is also a board member of Patient Focused Medicines Development, an international multi-stakeholder effort to bring patients into the heart of medicine research and development. Neil regularly works with patient groups, healthcare decision-makers and the industry to collectively develop approaches that benefit patients. 

As SVP of Clinical Research, at The Michael J. Fox Foundation (MJFF), Katie Kopil focuses on building the Foundation’s capacity as an unprecedented stakeholder in Parkinson’s drug development — a nimble, patient-focused problem-solver whose efforts are demonstrably accelerating progress toward treatment breakthroughs. Katie leads MJFF’s clinical research strategy including funding for clinical stage therapeutic programs, development of patient-centered endpoints for use in clinical trials, investments in landmark Parkinson's natural history studies including the Parkinson's Progression Markers Initiative, programs critical to patient engagement in research, and innovation to clarify market access pathways for treatments that make a difference in the community. Prior to joining the Foundation, Katie completed doctoral and postdoctoral training in neuroscience and bioengineering respectively at the University of Pennsylvania. Her research focused on brain injury that occurs during acute trauma such as cardiac arrest and concussion. Katie also helped speed research as a clinical trial coordinator at Memorial Sloan-Kettering Cancer Center in NYC, which is where her dual passions for science and serving patients first intersected. Katie graduated from Princeton University with a BA in Psychology and holds a PhD in Neuroscience from the University of Pennsylvania. She lives in New Jersey with her husband and two young children.

Kate Morgan is Head of Policy and Access at Myeloma Patients Europe (MPE). She holds a Bachelor’s degree in Government from the London School of Economics and Political Sciences and a Master’s degree in International and European Politics from the University of Edinburgh. Her main area of interest is health policy, with a specific focus on policies affecting drug development and access in European countries.

Kate previously worked for eight years on the Policy Team at Myeloma UK, where she influenced a range of policy, HTA and reimbursement decisions affecting patient access to good quality care and effective medicines. She represented the patient voice in a number of patient and public advisory panels in the UK healthcare system, including for the Scottish Medicines Consortium, the health technology assessment (HTA) body in Scotland on optimising patient involvement in decision-making.

She has also been involved in a wide-range of patient organisation and involvement networks, both nationally and internationally – most recently joining the HTAi Interest Group for Patient and Citizen Involvement in HTA (PCIG) steering committee.

Kate currently lives and works in Edinburgh, Scotland.